Pharmacology/Pharmaceutical Industry
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
Risk of cancer with angiotensin-receptor blockers increases with cumulative exposure: Meta-regression analysis of randomized trials.
4 Mar, 2022 | 08:49h | UTCCommentary: ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again – Medscape (free registration required)
RCT: Nirsevimab for prevention of RSV in healthy late-preterm and term infants.
3 Mar, 2022 | 09:42h | UTCCommentaries:
Nirsevimab Protects Late-Preterm, Term Infants from RSV-Related Lower RTI, Study Finds – AJMC
Nirsevimab Prophylaxis Wards Off RSV Infections in Healthy Infants— Monoclonal antibody showed 74.5% efficacy against RSV infections requiring medical care – MedPage Today (free registration required)
Related: Randomized trial: Single-dose nirsevimab for prevention of RSV in preterm infants
M-A: Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19.
3 Mar, 2022 | 08:49h | UTCEditorial: Treatment of severe covid-19 with interleukin 6 receptor inhibition – BMJ Medicine
Related study (just published): Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis – JAMA Network Open
Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.
3 Mar, 2022 | 08:43h | UTCMyocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong – JAMA Pediatrics
Commentary: Study: Dosing change could reduce COVID-19 vaccine heart side effect in teens – UPI
Related:
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
M-A: Association of tranexamic acid administration with mortality and thromboembolic events in patients with traumatic injury.
3 Mar, 2022 | 07:57h | UTCRelated:
Meta-analysis: Efficacy and safety of tranexamic acid in acute traumatic brain injury
Editorial: Is Tranexamic Acid Going to CRASH the Management of Traumatic Brain Injury?
M-A: Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma.
3 Mar, 2022 | 07:59h | UTC
Prescribing Nirmatrelvir–Ritonavir for Covid-19: How to recognize and manage drug–drug interactions.
2 Mar, 2022 | 09:01h | UTCRelated:
Pfizer antiviral pills may be risky with other medications – NBC News
[Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.
1 Mar, 2022 | 08:54h | UTCCommentaries:
Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT
More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP
Review: CRISPR in cancer biology and therapy.
27 Feb, 2022 | 22:27h | UTCCRISPR in cancer biology and therapy – Nature Reviews Cancer (if the link is paywalled, try this one)
M-A: Fetal and maternal outcomes after maternal biologic use during conception and pregnancy.
25 Feb, 2022 | 10:43h | UTC
RCT: Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine.
24 Feb, 2022 | 10:20h | UTCCommentary: Suspend Methotrexate for RA Patients Getting COVID Vax?— It’s not a simple choice, Brazilian study suggests (free registration required)
[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
24 Feb, 2022 | 10:30h | UTCFourth dose of COVID vaccine offers only slight boost against Omicron infection – Nature
Original Study: 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC – medRxiv
Two large populational-based studies find a slightly increased risk of thrombotic events following AstraZeneca COVID-19 vaccination.
24 Feb, 2022 | 10:23h | UTCCommentaries:
Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD
ASCO Report: Use of Biosimilar Medications in Oncology.
24 Feb, 2022 | 10:08h | UTCUse of Biosimilar Medications in Oncology – JCO Oncology Practice
News Release: New ASCO Report Clarifies Potential Value and Utility of Biosimilars in Oncology – ASCO Daily News
USPSTF Draft Statement: Statin use for the primary prevention of cardiovascular disease in adults.
23 Feb, 2022 | 10:45h | UTCCommentary: USPSTF Updates Guidance on Statins for Primary Prevention of CVD – HealthDay
RCT: Sublingual dexmedetomidine reduces mild to moderate acute agitation in patients with bipolar disorder.
23 Feb, 2022 | 10:18h | UTCEffect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Sublingual Dexmedetomidine as a Potential New Treatment for Agitation – JAMA (free for a limited period)
Commentary on Twitter
Randomized clinical trial found sublingual #dexmedetomidine at a dose of 180 μg or 120 μg reduced mild to moderate agitation in patients with #bipolar disorder. https://t.co/1VK2e15F7s pic.twitter.com/0oHw6eVMIP
— JAMA (@JAMA_current) February 22, 2022
AGA clinical practice update on de-prescribing of proton pump inhibitors.
22 Feb, 2022 | 10:12h | UTCRelated:
Deprescribing proton pump inhibitors guideline
Review: Deprescribing Proton Pump Inhibitors
Meta-analysis finds low risk of a second allergic reaction to SARS-CoV-2 mRNA vaccines in patients with an allergic reaction with the first dose.
22 Feb, 2022 | 10:05h | UTC
Commentary on Twitter
Systematic review and meta-analysis of 22 studies and 1366 patients found that there was a low risk of repeat allergic reaction to a second #COVID19 mRNA vaccine dose in people who had immediate allergic reaction with the first dose. https://t.co/NQSXBJwa6r
— JAMA Internal Medicine (@JAMAInternalMed) February 21, 2022
Opinion by Dr. Eric Topol | Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed.
22 Feb, 2022 | 10:07h | UTCWhy one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed – The Guardian
Commentary from the author on Twitter (thread – click for more)
My new essay @guardian
"Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed"https://t.co/RaBUpET2CZ
Summarizes extensive new evidence that confirmed Prior Covid ("Natural Immunity" or NI) + 1-shot is as protective as 3-shots /1— Eric Topol (@EricTopol) February 20, 2022
[Preprint] A large-scale observational study in Chile found CoronaVac (an inactivated SARS-CoV-2 vaccine) was associated with an effectiveness of 74.5% against infection, 91.0% against hospitalization, and 93.8% against ICU admission in children aged 6 to 16 years.
22 Feb, 2022 | 09:58h | UTCCommentary: Full schedule of CoronaVac vaccine shown to be highly effective in children – News Medical
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy.
22 Feb, 2022 | 08:15h | UTC
RCT: In patients with mild to moderate Covid-19 and comorbidities, treatment with Ivermectin did not reduce the risk of disease progression.
21 Feb, 2022 | 09:34h | UTCCommentaries:
Ivermectin doesn’t prevent severe disease from Covid-19, new study finds – CNN
Ivermectin futile for mild to moderate COVID-19, study finds – CIDRAP
Related:
Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.
Long-term consequences of the misuse of ivermectin data.
Ivermectin: How false science created a Covid ‘miracle’ drug.
Fraudulent ivermectin studies open up new battleground between science and misinformation.
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Ivermectin: Cochrane’s most talked about review so far, ever. Why?
Flawed ivermectin preprint highlights challenges of COVID drug studies.
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
Why was a major study on ivermectin for covid-19 just retracted?
RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.
RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.
21 Feb, 2022 | 09:33h | UTC
RCT: Sub dissociative dose of ketamine with haloperidol vs. fentanyl on pain reduction in patients with acute pain in the emergency department.
21 Feb, 2022 | 08:37h | UTCSub dissociative dose of ketamine with haloperidol versus fentanyl on pain reduction in patients with acute pain in the emergency department; a randomized clinical trial – The American Journal of Emergency Medicine (link to abstract – $ for full-text)